SCF IND PACKAGE FRAMEWORK
AMX-202
Investigational New Drug (IND) Application Blueprint
PROJECT AMMONEX-HE
Document Code: SCF-AMMONEX-HE-IND-0001
Candidate: AMX-202
Development Class: Small Molecule / Semi-Synthetic Botanical-Derived New Chemical Entity (Proposed)
Indication: Hepatic Encephalopathy (HE)
Regulatory Pathway: IND → Phase I (FIH) → Phase II → Phase III → NDA (505(b)(1) anticipated unless development strategy changes)
Purpose: Establish the complete FDA-aligned IND dossier architecture required for submission and initiation of First-In-Human clinical studies. FDA IND applications require nonclinical data, CMC information, and clinical protocols sufficient to support human exposure.
SECTION I — IND EXECUTIVE SUMMARY
Product Name
AMX-202
Pharmacologic Class
Hepatoenteric Nitrogen Homeostasis Modulator
Proposed Clinical Indication
Treatment of hyperammonemia-associated hepatic encephalopathy.
Primary Mechanistic Hypothesis
AMX-202 reduces ammonia burden through coordinated modulation of:
- Gut ammonia production
- Hepatic nitrogen metabolism
- Gut barrier integrity
- Neuroinflammatory signaling
SECTION II — FDA IND STRUCTURE
Module 1
Administrative Information
Required Components
- FDA Form 1571
- FDA Form 1572
- Financial disclosures
- Investigator information
- IRB information
- Environmental assessment/categorical exclusion
- Cross-reference letters
Deliverables
Document | Status |
Form 1571 | Draft |
Form 1572 | Draft |
Investigator Package | Required |
IRB Package | Required |
MODULE 2
OVERALL SUMMARIES
2.1 Quality Overall Summary (QOS)
Contents
- API description
- Formulation overview
- Manufacturing process summary
- Stability overview
2.2 Nonclinical Overview
Contents
- Pharmacology summary
- ADME summary
- Toxicology summary
- Risk assessment
2.3 Clinical Overview
Contents
- Rationale for human exposure
- Risk-benefit analysis
- FIH strategy
MODULE 3
CHEMISTRY, MANUFACTURING AND CONTROLS (CMC)
3.1 Drug Substance
Identity
Candidate:
AMX-202
Required Information
- Chemical name
- Structure
- Molecular weight
- Synthetic route
- Specifications
3.2 Manufacturing Process
Required Elements
- Raw materials
- Process flow diagram
- Critical process parameters
- Impurity controls
3.3 Drug Product
Dosage Form
Proposed:
Oral capsule
Strength
To be established from toxicology and PK studies.
3.4 Analytical Methods
Validation Required
Assay | Purpose |
HPLC | Purity |
LC-MS | Identity |
Dissolution | Release |
Stability | Shelf-life |
3.5 Stability Program
Required Conditions
- Long-term
- Accelerated
- Stress testing
Deliverable
IND-supporting shelf-life justification.
MODULE 4
NONCLINICAL STUDIES
4.1 Pharmacology
Primary Pharmacology
Gut Axis
- Ammonia production
- Urease-associated pathways
- Microbiome modulation
Liver Axis
- Nitrogen metabolism
- Urea-cycle support
- Mitochondrial function
Brain Axis
- Neuroinflammation
- Astrocyte stress
4.2 Secondary Pharmacology
Systems
- Cardiovascular
- Respiratory
- CNS
4.3 ADME
Absorption
- Oral bioavailability
- Intestinal permeability
Distribution
- Tissue distribution
- Portal circulation exposure
Metabolism
- Microsomal stability
- CYP interactions
Excretion
- Renal clearance
- Biliary elimination
4.4 Toxicology Package
Genetic Toxicology
Required:
- Ames
- Micronucleus
- Chromosomal aberration
Safety Pharmacology
Required:
- Cardiovascular
- Respiratory
- CNS
Repeat Dose Toxicology
Species | Duration |
Rodent | 28 Days |
Non-Rodent | 28 Days |
Toxicokinetics
Required:
- Exposure-response relationship
- NOAEL determination
MODULE 5
CLINICAL INVESTIGATION PLAN
Phase I
Study Design
Randomized
Placebo-controlled
Double-blind
Single Ascending Dose (SAD)
Multiple Ascending Dose (MAD)
FDA clinical phase framework aligns Phase I with safety, tolerability, PK, and dose characterization objectives.
SECTION III
INVESTIGATOR BROCHURE (IB)
Required Chapters
1. Executive Summary
2. Product Description
3. Pharmacology
4. Toxicology
5. Clinical Rationale
6. Risk Assessment
7. FIH Dosing Strategy
8. Safety Monitoring Plan
SECTION IV
FIRST-IN-HUMAN (FIH) SYNOPSIS
Study Title
A Phase I Randomized, Double-Blind, Placebo-Controlled Study of AMX-202 in Healthy Adult Volunteers.
Objectives
Primary
Assess:
- Safety
- Tolerability
Secondary
Characterize:
- Pharmacokinetics
- Food effect
- Exposure-response relationships
Exploratory
Evaluate:
- Plasma ammonia
- Nitrogen metabolism biomarkers
SECTION V
STARTING DOSE RATIONALE FRAMEWORK
Required Inputs
Before FIH:
- NOAEL (most sensitive species)
- Toxicokinetic exposure
- Safety pharmacology findings
FDA Standard Translation Logic
- Determine animal NOAEL.
- Convert to Human Equivalent Dose (HED).
- Apply safety factor.
- Establish Maximum Recommended Starting Dose (MRSD).
Because no actual toxicology data exist yet, no scientifically valid starting dose can currently be proposed.
SECTION VI
PRE-IND BRIEFING PACKAGE
FDA Questions
Question 1
Does FDA agree with the proposed pharmacology package?
Question 2
Are the selected HE animal models adequate?
Question 3
Is the proposed toxicology strategy sufficient to support FIH?
Question 4
Are the proposed biomarkers acceptable?
Question 5
Does FDA agree with the Phase I design?
SECTION VII
CRITICAL IND READINESS CHECKLIST
CMC
- Drug substance characterized
- GMP process established
- Stability package completed
Status
Pending
Pharmacology
- MoA validated
- Target engagement demonstrated
Status
Pending
Toxicology
- GLP studies completed
- NOAEL established
Status
Pending
Clinical
- Protocol finalized
- Investigator brochure finalized
Status
Pending
SECTION VIII
IND SUBMISSION DECISION GATE
GO CRITERIA
Nonclinical
- Robust efficacy signal
- Mechanistic confirmation
- Acceptable safety margins
CMC
- Reproducible manufacturing
- IND-supportive stability
Clinical
- FDA concurrence on FIH strategy
NO-GO CRITERIA
- Unacceptable toxicity
- Poor exposure
- Weak efficacy
- Manufacturing instability
NEXT STRATEGIC COMMAND
FIH PROTOCOL
Outputs:
- Complete Phase I protocol synopsis
- SAD cohort architecture
- MAD cohort architecture
- Safety monitoring committee charter
- Biomarker sampling schedule
- PK/PD analysis plan
- Dose-escalation decision rules
MASTER REGISTRY INDEX
SCF-AMMONEX-HE-IND-0001 — IND Package Framework
SCF-AMMONEX-HE-CMC-0002 — CMC Development Package
SCF-AMMONEX-HE-NONCL-0003 — Nonclinical Dossier
SCF-AMMONEX-HE-IB-0004 — Investigator Brochure Framework
SCF-AMMONEX-HE-FIH-0005 — First-In-Human Development Plan
SCF-AMMONEX-HE-REG-0006 — Regulatory Strategy Package
SCF-AMMONEX-HE-NDA-0007 — Long-Term Registration Pathway